Three independent discounted-cash-flow-style models value Vertex Pharmaceuticals Inc every trading day. 0 of 3 currently price VRTX above its market price.
| Free Cash Flow model | $192.87 |
| Excess Profit model | $287.16 |
| Residual Earnings model | $87.53 |
| Dividend Discount model | — |
| Piotroski F-Score | 6 / 9 |
| Return on invested capital | +15.1% |
| Net debt / EBITDA | -0.5× |
| Gross margin | +86.2% |
| Revenue CAGR | +10.4% |
| Cash conversion | 0.9× |
| Dividend yield | — |
| Buyback yield | +0.9% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open VRTX in StockKitty